Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Estrone | Estrone may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Estradiol | Estradiol may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Mestranol | Mestranol may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Estriol | Estriol may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Tibolone | Tibolone may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Zeranol | Zeranol may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Equol | Equol may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Promestriene | Promestriene may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Formononetin | Formononetin may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Estetrol | Estetrol may increase the thrombogenic activities of Telisotuzumab vedotin. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Telisotuzumab vedotin. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Telisotuzumab vedotin. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Telisotuzumab vedotin. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Telisotuzumab vedotin. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Telisotuzumab vedotin. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Telisotuzumab vedotin. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Telisotuzumab vedotin. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Telisotuzumab vedotin. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Telisotuzumab vedotin. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Telisotuzumab vedotin. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Telisotuzumab vedotin. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Telisotuzumab vedotin. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Telisotuzumab vedotin. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Telisotuzumab vedotin. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Telisotuzumab vedotin. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Telisotuzumab vedotin. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Telisotuzumab vedotin. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Telisotuzumab vedotin. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Telisotuzumab vedotin. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Telisotuzumab vedotin. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Telisotuzumab vedotin. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Telisotuzumab vedotin. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Telisotuzumab vedotin. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Telisotuzumab vedotin. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Telisotuzumab vedotin. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Telisotuzumab vedotin. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Telisotuzumab vedotin. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Telisotuzumab vedotin. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Telisotuzumab vedotin. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Telisotuzumab vedotin. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Telisotuzumab vedotin. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Telisotuzumab vedotin. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Telisotuzumab vedotin. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Telisotuzumab vedotin. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Telisotuzumab vedotin. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Telisotuzumab vedotin. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Telisotuzumab vedotin. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Telisotuzumab vedotin. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Telisotuzumab vedotin. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Telisotuzumab vedotin. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Telisotuzumab vedotin. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Telisotuzumab vedotin. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Telisotuzumab vedotin. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Telisotuzumab vedotin. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Telisotuzumab vedotin. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Telisotuzumab vedotin. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Telisotuzumab vedotin. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Telisotuzumab vedotin. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Telisotuzumab vedotin. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Telisotuzumab vedotin. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Telisotuzumab vedotin. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Telisotuzumab vedotin. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Telisotuzumab vedotin. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Telisotuzumab vedotin. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Telisotuzumab vedotin. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Telisotuzumab vedotin. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Telisotuzumab vedotin. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Telisotuzumab vedotin. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Telisotuzumab vedotin. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Telisotuzumab vedotin. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Telisotuzumab vedotin. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Telisotuzumab vedotin. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Telisotuzumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Telisotuzumab vedotin. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Telisotuzumab vedotin. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Telisotuzumab vedotin. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Telisotuzumab vedotin. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Telisotuzumab vedotin. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Telisotuzumab vedotin. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Telisotuzumab vedotin. |